Lukas Rindlisbacher

Lukas Rindlisbacher

Auto-generated profile, based on publicly available information

Lukas Rindlisbacher

Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2023 in Science Immunology
Verified
Journal Article
Open access
SMSonja Marinović
Sonja Marinović
MLMaja Lenartić
Maja Lenartić
KMKarlo Mladenić
Karlo Mladenić
MŠMarko Šestan
Marko Šestan
IKInga Kavazović
Inga Kavazović
FWFelix Martinus Wensveen
Felix Martinus Wensveen
Metabolic-associated fatty liver disease (MAFLD) is a spectrum of clinical manifestations ranging from benign steatosis to cirrhosis. A key event in the pathophysiology of MAFLD is the development of nonalcoholic steatohepatitis (NASH), which can potentially lead to fibrosis and hepatocellular carcinoma, but the triggers of MAFLD-associated inflammation are not well understood. We have observed that lipid accumulation in hepatocytes induces expression of ligands specific to the activating immune receptor NKG2D. Tissue-resident innate-like T cells, most notably γδ T cells, are activated through NKG2D and secrete IL-17A. IL-17A licenses hepatocytes to produce chemokines that recruit proinflammatory cells into the liver, which causes NASH and fibrosis. NKG2D-deficient mice did not develop fibrosis in dietary models of NASH and had a decreased incidence of hepatic tumors. The frequency of IL-17A + γδ T cells in the blood of patients with MAFLD correlated directly with liver pathology. Our findings identify a key molecular mechanism through which stressed hepatocytes trigger inflammation in the context of MAFLD.

24 May 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
TLThomas Look
Thomas Look
EPEmanuele Puca
Emanuele Puca
MBMarcel Bühler
Marcel Bühler
DKDaniel Kirschenbaum
Daniel Kirschenbaum
RLRoberto De Luca
Roberto De Luca
TWTobias Weiss
Tobias Weiss
Glioblastoma is the most aggressive primary brain tumor with an unmet need for more effective therapies. Here, we investigated combination therapies based on L19TNF, an antibody-cytokine fusion protein based on tumor necrosis factor that selectively localizes to cancer neovasculature. Using immunocompetent orthotopic glioma mouse models, we identified strong anti-glioma activity of L19TNF in combination with the alkylating agent CCNU, which cured the majority of tumor-bearing mice, whereas monotherapies only had limited efficacy. In situ and ex vivo immunophenotypic and molecular profiling in the mouse models revealed that L19TNF and CCNU induced tumor DNA damage and treatment-associated tumor necrosis. In addition, this combination also up-regulated tumor endothelial cell adhesion molecules, promoted the infiltration of immune cells into the tumor, induced immunostimulatory pathways, and decreased immunosuppression pathways. MHC immunopeptidomics demonstrated that L19TNF and CCNU increased antigen presentation on MHC class I molecules. The antitumor activity was T cell dependent and completely abrogated in immunodeficient mouse models. On the basis of these encouraging results, we translated this treatment combination to patients with glioblastoma. The clinical translation is ongoing but already shows objective responses in three of five patients in the first recurrent glioblastoma patient cohort treated with L19TNF in combination with CCNU (NCT04573192).

18 December 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
CSColin Sparano
Colin Sparano
DSDarío Solís-Sayago
Darío Solís-Sayago
NZNathan Sébastien Zangger
Nathan Sébastien Zangger
LRLukas Rindlisbacher
Lukas Rindlisbacher
HHHannah Van Hove
Hannah Van Hove
STSonia Tugues
Sonia Tugues
Group 1 innate lymphoid cells (ILCs) encompass NK cells and ILC1s, which have non-redundant roles in host protection against pathogens and cancer. Despite their circulating nature, NK cells can establish residency in selected tissues during ontogeny, forming a distinct functional subset. The mechanisms that initiate, maintain, and regulate the conversion of NK cells into tissue-resident NK (trNK) cells are currently not well understood. Here, we identify autocrine transforming growth factor-β (TGF-β) as a cell-autonomous driver for NK cell tissue residency across multiple glandular tissues during development. Cell-intrinsic production of TGF-β was continuously required for the maintenance of trNK cells and synergized with Hobit to enhance cytotoxic function. Whereas autocrine TGF-β was redundant in tumors, our study revealed that NK cell–derived TGF-β allowed the expansion of cytotoxic trNK cells during local infection with murine cytomegalovirus (MCMV) and contributed to viral control in the salivary gland. Collectively, our findings reveal tissue-specific regulation of trNK cell differentiation and function by autocrine TGF-β1, which is relevant for antiviral immunity.

18 April 2023 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
MLMarlene Langenbach
Marlene Langenbach
SGSophie Giesler
Sophie Giesler
SRStefan Richtsfeld
Stefan Richtsfeld
SCSara Costa-Pereira
Sara Costa-Pereira
LRLukas Rindlisbacher
Lukas Rindlisbacher
RZRobert Zeiser
Robert Zeiser
The treatment of patients with metastatic melanoma with immune checkpoint inhibitors (ICI) leads to impressive response rates but primary and secondary resistance to ICI reduces progression-free survival. Novel strategies that interfere with resistance mechanisms are key to further improve patient outcome during ICI therapy. P53 is often inactivated by mouse-double-minute-2 (MDM2), which may decrease immunogenicity of melanoma cells. We analyzed primary patient-derived melanoma cell lines, performed bulk sequencing analysis of patient-derived melanoma samples, and used melanoma mouse models to investigate the role of MDM2-inhibition for enhanced ICI therapy. We found increased expression of IL15 and MHC-II in murine melanoma cells upon p53 induction by MDM2-inhibition. MDM2-inhibitor induced MHC-II and IL15-production, which was p53 dependent as Tp53 knockdown blocked the effect. Lack of IL15-receptor in hematopoietic cells or IL15 neutralization reduced the MDM2-inhibition/p53-induction–mediated antitumor immunity. P53 induction by MDM2-inhibition caused anti-melanoma immune memory as T cells isolated from MDM2-inhibitor–treated melanoma-bearing mice exhibited anti-melanoma activity in secondary melanoma-bearing mice. In patient-derived melanoma cells p53 induction by MDM2-inhibition increased IL15 and MHC-II. IL15 and CIITA expressions were associated with a more favorable prognosis in patients bearing WT but not TP53-mutated melanoma. Implications: MDM2-inhibition represents a novel strategy to enhance IL15 and MHC-II–production, which disrupts the immunosuppressive tumor microenvironment. On the basis of our findings, a clinical trial combining MDM2-inhibition with anti–PD-1 immunotherapy for metastatic melanoma is planned.

3 May 2023
Verified
Other
Open access
PDF file
MLMarlene Langenbach
Marlene Langenbach
SGSophie Giesler
Sophie Giesler
SRStefan Richtsfeld
Stefan Richtsfeld
SCSara Costa-Pereira
Sara Costa-Pereira
LRLukas Rindlisbacher
Lukas Rindlisbacher
RZRobert Zeiser
Robert Zeiser
Supplementary Figures Legends and Methods

17 June 2026
Verified
Other
Open access
PDF file
MLMarlene Langenbach
Marlene Langenbach
SGSophie Giesler
Sophie Giesler
SRStefan Richtsfeld
Stefan Richtsfeld
SCSara Costa-Pereira
Sara Costa-Pereira
LRLukas Rindlisbacher
Lukas Rindlisbacher
RZRobert Zeiser
Robert Zeiser
Supplementary Figures Legends and Methods